Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:GERN

Geron Q3 2026 Earnings Date & Estimates

Geron logo
$1.20 -0.02 (-1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 0.00 (0.00%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Geron is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Geron in Q3 2026

Geron is expected to post earnings of -$0.01 per share on revenue of $60.70 million. In the same quarter a year earlier Geron reported -$0.03 per share on revenue of $47.23 million. Geron last reported on August 5, 2026, posting -$0.02 per share and missing the -$0.0089 consensus estimate. Geron has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.01
Expected Revenue
$60.70 million
Prior-Year EPS
-$0.03
Prior-Year Revenue
$47.23 million
Expected Revenue Growth
+28.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.02 (Missed by -$0.0111)
Last Quarter Revenue
$57.48 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Geron Q3 2026 Earnings FAQ

Geron (NASDAQ:GERN) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Geron's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Geron to post earnings of -$0.01 per share for Q3 2026.

The consensus revenue estimate for Geron is $60.70 million for Q3 2026.

Geron Earnings Headlines

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
October 13 at 2:52 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-geron-corporation-insiders-breach-their-fiduciary-duties-to-shareholders-302907357.html
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
October 12 at 9:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/12/3378848/35501/en/geron-corporation-announces-oral-presentations-highlighting-imetelstat-at-international-hematology-congresses-in-europe-and-asia.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 13 at 1:00 AM  |  Base Camp Trading (Ad)
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
September 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-geron-corporation-insiders-breach-their-fiduciary-duties-to-shareholders-302890718.html
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
September 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/geron-investigation-initiated-kahn-swick--foti-llc-investigates-the-officers-and-directors-of-geron-corporation---gern-302890626.html
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/18/3364933/35501/en/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
See More Geron Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Geron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Geron and other key companies, straight to your email.

About Geron

Geron (NASDAQ:GERN) (NASDAQ:GERN) is a biopharmaceutical company focused on developing and commercializing treatments for blood cancers and other serious hematologic disorders. Its lead product is Rytelo (imetelstat), a telomerase inhibitor designed to target malignant cells by interfering with telomere maintenance.

In 2024, the U.S. Food and Drug Administration approved Rytelo for adults with lower-risk myelodysplastic syndromes who require regular red blood cell transfusions and have not responded adequately to, or have lost response to, or are ineligible for, erythropoiesis-stimulating agents. Geron markets Rytelo in the United States and continues to evaluate imetelstat in additional hematologic malignancies, including myelofibrosis.

Founded in 1990, Geron initially conducted research involving telomeres, telomerase and human embryonic stem cells before concentrating its business on oncology. The company is headquartered in Foster City, California, and is led by John A. Scarlett, who serves as chairman and chief executive officer.

View Geron Profile
Earnings Tools